ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY
Changes in Board, Management or Compensation
Axsome Therapeutics Stockholders Approve Director Elections and Auditor Appoi...
Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Annual Report to Security Holders
Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q1
FY 2024
Q3
Q2
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
SEC Staff Correspondence
Submission Upload
Correspondence
Confidential Treatment Order